Pluristem Therapeutics (PSTI) Announces Plan to Expand Research & Development of Radiation Exposure Treatment

Pluristem Therapeutics, Inc. (Nasdaq: PSTI) today announced that following preliminary discussions with several governmental authorities, it will expand its research and development efforts on an acute radiation exposure treatment. The announcement comes as governments around the world have broadened their search for easily administered and effective radiation countermeasures. Liat Flaishon, MD, PhD, recently appointed Pluristem's Director of Business Development, will lead the company's development efforts.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• When do we “run out” of oil stockpiles?
• Why this Wall Street strategist says the "trade is long gold"
• Morgan Stanley is out with its gold price outlook for 2027